Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 CAR T cells in B-cell malignancies
NCT03448393Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2018
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of bispecific CD19/CD22 CAR-T cells in acute lymphoblastic leukemia (ALL) and B cell lymphoma, sponsored by National Cancer Institute. Started Mar 2018; status: completed.
02
Drugs
bispecific CD19/CD22 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT03448393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03448393.